Unicycive Therapeutics UNCY
NASDAQ UNCY
$3.89 -0.05 (-1.27%)
At close: Oct 23, 2026 · 4:00 PM EDT

Unicycive Therapeutics (UNCY) Return on Sales [ROS] (2022 - 2023)

Updated

Unicycive Therapeutics' Return on Sales [ROS] came in at -3077.78% for Q4 2023, down 146.37 percentage points from the prior quarter.

Analysis

Unicycive Therapeutics (UNCY) Return on Sales [ROS] (2022 - 2023) Analysis & Trends

For FY2023, Unicycive Therapeutics' Return on Sales [ROS] was -3077.63%, down 1179.42 percentage points from FY2022.

  • Going back by year, Return on Sales [ROS] was -1898.21% in FY2022.
  • Business Quant data shows UNCY's Return on Sales [ROS] at -2931.41% (Q3 2023), -1193.30% (Q2 2023) and -622.52% (Q1 2023) in the three quarters before Q4 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 24.35%
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn 37.86%
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn -3.52%
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 32.97%
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn 20.57%
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn 34.95%
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn -133.21%
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn 28.37%
10 Unicycive Therapeutics 108.36 Mn -91.62 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -3,077.78%
Sep 30, 2023 -2,931.41%
Jun 30, 2023 -1,193.30%
Mar 31, 2023 -622.52%
Sep 30, 2022 -584.02%
API Access

Unicycive Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=UNCY&period=max&api_key=YOUR_API_KEY